ES2128434T3 - Compuestos de alquilamino-etinil-alanina-amino-diol terminados en piridinilo/quinolinilo para el tratamiento de la hipertension. - Google Patents

Compuestos de alquilamino-etinil-alanina-amino-diol terminados en piridinilo/quinolinilo para el tratamiento de la hipertension.

Info

Publication number
ES2128434T3
ES2128434T3 ES93919921T ES93919921T ES2128434T3 ES 2128434 T3 ES2128434 T3 ES 2128434T3 ES 93919921 T ES93919921 T ES 93919921T ES 93919921 T ES93919921 T ES 93919921T ES 2128434 T3 ES2128434 T3 ES 2128434T3
Authority
ES
Spain
Prior art keywords
piridinyl
quinolinyl
ethinyl
alkylamino
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93919921T
Other languages
English (en)
Inventor
Gunnar J Hanson
Robert E Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2128434T3 publication Critical patent/ES2128434T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

LOS COMPUESTOS CARACTERIZADOS GENERALMENTE COMO DERIVADOS DEL AMINO DIOL DE ALQUILAMINO-ETINIL-ALANINA TERMINALES EN PIRIDINIL-QUINOLINIL SON UTILES COMO INHIBIDORES DE LA RENINA PARA EL TRATAMIENTO DE LA HIPERTENSION. COMPUESTOS DE PARTICULAR INTERES SON AQUELLOS DE LA FORMULA (I), EN DONDE A SE SELECCIONA ENTRE CO Y SO2; X SE SELECCIONA ENTRE UN ATOMO DE OXIGENO Y METILENO; B SE SELECCIONA ENTRE PIRIDINILO, QUINOLINILO, ISOQUINOLINO, CLOROQUINOLINILO, TETRAHIDROQUINOLINILO Y TETRAHIDROQUINOLINILO SUSTITUIDO CON OXO; R1 SE SELECCIONA ENTRE HIBRIDO, METILO, ETILO, ISOPROPILO Y N-PROPILO; R2 ES FENILMETILO; CADA R3 Y R5 ES HIBRIDO; R4 SE SELECCIONA ENTRE ( ), EN DONDE V SE SELECCIONA ENTRE HIBRIDO Y METILO; R6 ES CICLOHEXILMETILO; R7 SE SELECCIONA ENTRE ISOBUTILO, CICLOPROPILO Y CICLOPROPILMETILO; EN DONDE Q ES UN NUMERO SELECCIONADO ENTRE 0 Y 3; Y N ES UN NUMERO SELECCIONADO ENTRE 0 Y 3; TAMBIEN SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS COMPUESTOS.
ES93919921T 1992-08-14 1993-08-10 Compuestos de alquilamino-etinil-alanina-amino-diol terminados en piridinilo/quinolinilo para el tratamiento de la hipertension. Expired - Lifetime ES2128434T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/930,068 US5252591A (en) 1992-08-14 1992-08-14 Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Publications (1)

Publication Number Publication Date
ES2128434T3 true ES2128434T3 (es) 1999-05-16

Family

ID=25458881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93919921T Expired - Lifetime ES2128434T3 (es) 1992-08-14 1993-08-10 Compuestos de alquilamino-etinil-alanina-amino-diol terminados en piridinilo/quinolinilo para el tratamiento de la hipertension.

Country Status (11)

Country Link
US (3) US5252591A (es)
EP (1) EP0655058B1 (es)
JP (1) JPH08500116A (es)
AT (1) ATE177736T1 (es)
AU (1) AU4999493A (es)
CA (1) CA2138518A1 (es)
DE (1) DE69324019T2 (es)
DK (1) DK0655058T3 (es)
ES (1) ES2128434T3 (es)
GR (1) GR3030225T3 (es)
WO (1) WO1994004503A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508466A (en) * 1994-04-13 1996-04-16 G.D. Searle & Co. Synthesis of N-protected-α-substituted-glycine racemic esters by zinc-mediated addition of organic halide to glycine cation equivalent
KR20010033248A (ko) * 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
MXPA04004713A (es) * 2001-11-19 2005-08-16 Pharmacia & Up John Company Ll Aminoides utiles en el tratamiento de la enfermedad de alzheimer.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59227851A (ja) * 1983-06-09 1984-12-21 Sankyo Co Ltd レニン阻害作用を有するペプチド類
EP0181110A3 (en) * 1984-10-22 1988-05-11 Kissei Pharmaceutical Co. Ltd. Histidine derivatives as renin inhibitors
SU1676454A3 (ru) * 1984-11-30 1991-09-07 Санкио Компани Лимитед (Фирма) Способ получени пептидов или их фармацевтически приемлемых солей
DK34086A (da) * 1985-01-23 1986-07-24 Abbott Lab Peptidylaminodioler
JPS61236770A (ja) * 1985-04-15 1986-10-22 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
JPS6256458A (ja) * 1985-09-04 1987-03-12 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
IL81234A (en) * 1986-01-16 1992-09-06 Abbott Lab Peptidylaminodiols,process for their preparation and pharmaceutical compositions comprising them
WO1987004349A1 (en) * 1986-01-16 1987-07-30 Joseph Dellaria Peptide analogs
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
US4921855A (en) * 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
US4902706A (en) * 1988-07-01 1990-02-20 G. D. Searle & Co. Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents
IE902446A1 (en) * 1989-07-26 1991-02-13 Abbott Lab Peptidyl aminodiol renin inhibitors
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors

Also Published As

Publication number Publication date
ATE177736T1 (de) 1999-04-15
EP0655058A1 (en) 1995-05-31
US5434162A (en) 1995-07-18
AU4999493A (en) 1994-03-15
DE69324019D1 (de) 1999-04-22
EP0655058B1 (en) 1999-03-17
DE69324019T2 (de) 1999-08-05
GR3030225T3 (en) 1999-08-31
WO1994004503A1 (en) 1994-03-03
JPH08500116A (ja) 1996-01-09
DK0655058T3 (da) 1999-09-27
US5563154A (en) 1996-10-08
CA2138518A1 (en) 1994-03-03
US5252591A (en) 1993-10-12

Similar Documents

Publication Publication Date Title
ATE21894T1 (de) Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln.
AR241161A2 (es) "procedimiento para la preparacion de derivados n-aminoalquilen sustituidos de la glutarimida"
DE59712561D1 (de) Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
MX9805181A (es) Derivados de lactona a partir de derivados de 17.beta- carboxi, carbotio y amida androstano.
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
SE8404019D0 (sv) Oftalmiskt medel
SE8500878D0 (sv) Nya enkafalinderivat
UY25211A1 (es) Inhibidores de isoquinolinilguanidina uroquinasa
SE8505887D0 (sv) Indoler
ES2189941T3 (es) Derivados de nucleosidos aciclicos.
CO4290299A1 (es) Derivados de 1,5-benzodiazepina
DE69132689T2 (de) Biologisch aktive amine
FI852003L (fi) --laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel eller tillvaextbefraemjare vid boskapsuppfoedning eller som antioxidanter.
ES2128434T3 (es) Compuestos de alquilamino-etinil-alanina-amino-diol terminados en piridinilo/quinolinilo para el tratamiento de la hipertension.
SE7706346L (sv) Bensaminderivat
SE7811455L (sv) 2-imino-imidazolidin-derivat
ES2141148T3 (es) N-(dihidroxi-alquil)-etinil-alaninamidas terminadas en piperidinilo para el tratamiento de la hipertension.
ES455741A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
IT1254996B (it) Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
SE7609909L (sv) Nya penicilliner och forfarande for framstellning derav
SE8303913D0 (sv) Heterocykliska foreningar
ES2117003T3 (es) Derivados oligopeptidicos de hipoxantina dotados de actividad inmunomoduladora, y composiciones farmaceuticas que los contienen.
ES2136667T3 (es) Compuestos de etinil-alanina-amino-diol que tienen un grupo terminado en piperazinilo o un grupo terminado en piperazinil-alquilamino para el tratamiento de la hipertension.
AR248127A1 (es) Procedimiento para la preparacion de nuevas 2-aminotetralinas sustituidas en la posicion 8.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 655058

Country of ref document: ES